{"id":251177,"date":"2014-03-10T18:51:06","date_gmt":"2014-03-10T22:51:06","guid":{"rendered":"http:\/\/www.eugenesis.com\/okyanos-ceo-matt-feshbach-announces-appointment-of-institutes-marketing-executive-erika-rosenthal-to-international\/"},"modified":"2014-03-10T18:51:06","modified_gmt":"2014-03-10T22:51:06","slug":"okyanos-ceo-matt-feshbach-announces-appointment-of-institutes-marketing-executive-erika-rosenthal-to-international-2","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/okyanos-ceo-matt-feshbach-announces-appointment-of-institutes-marketing-executive-erika-rosenthal-to-international-2.php","title":{"rendered":"Okyanos CEO Matt Feshbach Announces Appointment of Institutes Marketing Executive Erika Rosenthal to International &#8230;"},"content":{"rendered":"<p><p>    Freeport, The Bahamas (PRWEB) March 10, 2014  <\/p>\n<p>    Matt Feshbach, CEO of Okyanos Heart Institute whose mission it    is to bring a new standard of care and better quality of life    to patients with coronary artery disease using cardiac stem    cell therapy has announced the appointment of Okyanos senior    vice president of marketing,     Erika Rosenthal, to the International Stem Cell Society    (STEMSO) Advisory Board. She will advise the trade organization    in a communications capacity to benefit the membership and the    mission.  <\/p>\n<p>        STEMSO is a member-based, international, non-profit 501(c)    6 trade association which promotes the interests of    organizational members of the global, adult stem cell    healthcare community. STEMSO provides information, education,    resources, advocacy and public awareness for the advancement of    adult stem cell research and therapy. The organization recently    hosted a global regenerative medicine conference in Freeport,    The Bahamas, entitled, Bridging the Gap: Research to Point of    Care which brought together experts in adult stem cell therapy    and regulations to discuss commercialization of therapies for    chronic disease in a safe, ethical, and compliant manner.  <\/p>\n<p>    STEMSO is an important organization to the field of stem cell    therapy and research, said Feshbach. Communications and    healthcare are both fields in which Erika excels, and so I am    pleased to see her lend her expertise for an important cause. I    look forward to the Okyanos Heart Institute executive team    continuing with such efforts for the greater good of medicine.  <\/p>\n<p>    Rosenthal was a 2008 recipient of the National Association of    Women Business Owners Business Woman of the Year award, and was    recognized in Business Leader Magazine as a Woman    Extraordinaire, for her business accomplishments and    contributions to the non-profit community. She is a former    faculty member of the University of California where she taught    Marketing and Hospitality Management.  <\/p>\n<p>    It is indeed an honor to work with STEMSO to advance their    cause to help advance adult stem cell research and therapy    worldwide, and to bring together leading researchers,    physicians, regulators and scientists to set standards for    ethical and responsible delivery of therapies as they become    available to the public worldwide, said Rosenthal. It is an    exciting time in medicine, and STEMSO is greatly needed to    bring collaboration and guidance between this impressive member    group of thought leaders.  <\/p>\n<p>    STEMSO is pleased to have Erika Rosenthal participate on    STEMSOs Advisory Board, said Douglas Hammond, president of    STEMSO. Non-profit trade associations are only as strong as    their member participation and leadership allows. If other    members or prospective organizational members were to support    STEMSO as Okyanos Heart Institute and Erika Rosenthal, there    would be no limit to STEMSOs impact in the Regenerative    Medicine Industry.  <\/p>\n<p>    About Okyanos Heart Institute: (Oh  key  AH  nos)    Based in Freeport, The Bahamas, Okyanos Heart Institutes    mission is to bring a new standard of care and a better quality    of life to patients with coronary artery disease using cardiac    stem cell therapy. Okyanos adheres to U.S. surgical center    standards and is led by Chief Medical Officer Howard T. Walpole    Jr., M.D., M.B.A., F.A.C.C., F.S.C.A.I. Okyanos Treatment    utilizes a unique blend of stem and regenerative cells derived    from ones own adipose (fat) tissue. The cells, when placed    into the heart via a minimally-invasive procedure, can    stimulate the growth of new blood vessels, a process known as    angiogenesis. Angiogenesis facilitates blood flow in the heart,    which supports intake and use of oxygen (as demonstrated in    rigorous clinical trials such as the PRECISE trial). The    literary name Okyanos, the Greek god of rivers, symbolizes    restoration of blood flow.  <\/p>\n<p>    END  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Link:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.prweb.com\/releases\/2014\/03\/prweb11645363.htm\/RK=0\/RS=Zl7ib.5qpyBWLnf57ii3gY7qiSQ-\" title=\"Okyanos CEO Matt Feshbach Announces Appointment of Institutes Marketing Executive Erika Rosenthal to International ...\">Okyanos CEO Matt Feshbach Announces Appointment of Institutes Marketing Executive Erika Rosenthal to International ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Freeport, The Bahamas (PRWEB) March 10, 2014 Matt Feshbach, CEO of Okyanos Heart Institute whose mission it is to bring a new standard of care and better quality of life to patients with coronary artery disease using cardiac stem cell therapy has announced the appointment of Okyanos senior vice president of marketing, Erika Rosenthal, to the International Stem Cell Society (STEMSO) Advisory Board. She will advise the trade organization in a communications capacity to benefit the membership and the mission.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/okyanos-ceo-matt-feshbach-announces-appointment-of-institutes-marketing-executive-erika-rosenthal-to-international-2.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-251177","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/251177"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=251177"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/251177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=251177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=251177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=251177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}